Table of contents
Library
The library contains direct access to the tables, graphics and topical boxes which appear in the 2011 annual report. Note that page numbers refer to the English print version of the report.
- Graphics
- Figure 1: Timeline of European drug policy documents
- Figure 2: Penalties in laws: possibility of imprisonment for possession of drugs for personal use (minor offences)
- Figure 3: Provision of selective prevention interventions as estimated by national experts
- Figure 4: Reports for offences related to drug use or possession for use and to drug supply in the EU Member States: indexed trends 2004-09 and breakdown by drug of reports for 2009
- Figure 5: Trends in last year prevalence of cannabis use among young adults (aged 15 to 34), countries with three surveys or more and grouped according to highest prevalence level (below 10 %, 10-15 %, above 15 %)
- Figure 6: Trends in last month prevalence of cannabis use and cigarettes smoking among 15- to 16-year-old school students in 17 European countries and the United States
- Figure 7: Prevalence of daily or almost daily cannabis use among young adults (15-34) by gender
- Figure 8: Trends in last year prevalence of use of amphetamines (top) and ecstasy (bottom) among young adults (aged 15-34)
- Figure 9: Last year prevalence of cocaine use among young adults (15-34) in Europe, Australia, Canada and the USA
- Figure 10: Trends in last year prevalence of cocaine use among young adults in the six highest EU Member States, Australia, Canada and the USA
- Figure 11: Estimates of the annual prevalence of problem opioid use (among population aged 15-64)
- Figure 12: Primary opioid users as a percentage of all reported drug treatment entrants in 2009
- Figure 13: Injecting as usual mode of administration among primary opioid users entering treatment in 2009
- Figure 14: Clients in opioid substitution treatment in the 15 pre-2004 and the 12 newer EU Member States — estimated numbers and indexed trends
- Figure 15: HIV infections newly diagnosed in injecting drug users in 2009 in Europe and central Asia
- Figure 16: Trends in newly reported HIV infections in injecting drug users in the five EU Member States reporting the highest rates
- Figure 17: Prevalence of HCV antibodies among injecting drug users
- Figure 18: Geographical availability of needle and syringe programmes at regional level
- Figure 19: Estimated mortality rates among all adults (15-64 years) due to drug-induced deaths
- Figure 20: Apparent country of origin of online shops offering 'legal highs' detected in the 2010 and 2011 Internet snapshots
- Tables
- Table 1: Recently adopted national drug policy documents
- Table 2: Estimates of drug-related public expenditure
- Table 3: Production, seizures, price and potency of herbal cannabis and resin
- Table 4: Prevalence of cannabis use in the general population — summary of the data
- Table 5: Seizures, price and purity of amphetamine, methamphetamine, ecstasy and LSD
- Table 6: Prevalence of amphetamines use in the general population — summary of the data
- Table 7: Prevalence of ecstasy use in the general population — summary of the data
- Table 8: Production, seizures, price and purity of cocaine and crack cocaine
- Table 9: Prevalence of cocaine use in the general population — summary of the data
- Table 10: Production, seizures, price and purity of heroin
- Table 11: International comparison of estimates of problem opioid users and numbers of clients in opioid substitution treatment
- Boxes
- Box, page 15: At a glance — estimates of drug use in Europe
- Box, page 21: Drug policy developments
- Box, page 22: Recession: the impact on interventions in the drugs area
- Box, page 25: Priorities for future research: EMCDDA Scientific Committee recommendations
- Box 2, page 25: ALICE RAP
- Box, page 30: 'Selected issue' on financing and cost of drug treatment
- Box, page 33: Drug user involvement
- Box, page 36: Training the European police
- Box, page 38: Developing indicators on drug markets, crime and supply reduction in Europe
- Box, page 45: Looking for a relationship between penalties and cannabis use
- Box, page 47: Adverse health effects of cannabis use
- Box, page 48: Medical use of cannabis in the United States
- Box, page 51: Diversifying the supply of precursors for synthetic drug production in Europe
- Box, page 59: Health consequences of amphetamines
- Box, page 63: Wholesale and retail drug prices: cocaine
- Box, page 67: Cocaine and alcohol
- Box, page 73: Major fall in opium production in Afghanistan
- Box, page 76: Opioids other than heroin
- Box, page 77: Heroin drought in Europe?
- Box, page 79: Heroin-assisted treatment
- Box, page 80: Oral substitution treatment in pregnancy
- Box, page 86: Tuberculosis among drug users
- Box 2, page 86: Prevention of infections among injecting drug users: ECDC–EMCDDA joint guidelines
- Box, page 89: Methadone and mortality
- Box, page 90: 'Selected issue': Mortality related to drug use — a comprehensive approach and public health implications
- Box, page 94: Main groups of new psychoactive substances monitored by the early-warning system
- Box, page 95: Risk assessment guidelines
- Box, page 96: Not so 'legal highs'
- Box, page 97: Policing newly controlled psychoactive substances
- Box 2, page 97: Wastewater analysis
